Tay-Sachs Carrier Screening by Enzyme and Molecular Analyses in the New York City Minority Population

Nikita Mehta, Gabriel A. Lazarin, Erica Spiegel, Kathleen Berentsen, Kelly Brennan, Jessica L. Giordano, Imran S. Haque, Ronald J. WapnerGenetic 2016 · DOI

TL;DR

This study investigates the effectiveness of Tay-Sachs disease (TSD) carrier screening using enzymatic analysis versus genetic sequencing in a non-Ashkenazi Jewish (non-AJ) population. The findings suggest that current enzymatic screening methods yield a high rate of inconclusive results and a poor correlation with actual pathogenic mutations in this demographic, pointing towards the need for ethnic-specific recalibration or a shift towards genetic sequencing.

What Problem Does This Paper Address?

Tay-Sachs disease (TSD) is a severe neurodegenerative disorder primarily associated with mutations in the HEXA gene. Historically, carrier screening for TSD has relied on measuring the activity of the Hexosaminidase A (Hex A) enzyme. While this method has been effective for the Ashkenazi Jewish (AJ) population, where specific mutations are prevalent, its utility in diverse, non-AJ populations is less understood. As interethnic marriages increase, identifying at-risk individuals becomes more challenging, and relying solely on self-reported ethnicity for targeted screening is insufficient. This paper addresses the gap in understanding the reliability and accuracy of enzymatic screening in non-AJ populations, particularly in New York City, where ethnic diversity is high. The authors question whether the established reference ranges for enzymatic assays, often derived from AJ populations, are appropriate for other ethnic groups and explore the performance of molecular analysis (specifically HEXA gene sequencing) as an alternative.

Methods

The study employed two primary methods for Tay-Sachs carrier screening:

  • Enzymatic Analysis (EA): Leukocyte Hex A activity was measured using a standard heat-inactivation fluorometric method with an artificial substrate. The percentage of Hex A activity (WBC Hex A%) was calculated. For one patient, testing was performed at an external laboratory with slightly different reference ranges.
  • Molecular Analysis:
    • Targeted Mutation Analysis: This involved screening for nine common pathogenic HEXA mutations and two pseudodeficiency alleles, primarily using high-throughput genotyping.
  • Next-Generation Sequencing (NGS): For a subset of patients with positive or inconclusive enzymatic results, the entire HEXA gene (exons 1-14) was sequenced. This method involved DNA isolation, fragmentation, adapter ligation, library preparation, multiplexing, and sequencing by synthesis. Variant classification followed ACMG guidelines.

The study design involved an initial screening of a diverse population using both enzymatic and targeted mutation analysis. Patients with positive or inconclusive enzymatic results, but negative targeted mutation analysis, were then offered full HEXA gene sequencing.

Datasets

The study utilized data from 508 self-reported African/African American or Hispanic patients who underwent screening between July 2013 and March 2014 at Columbia University Medical Center. This cohort represents a specific demographic within New York City, chosen for its ethnic diversity and the need for more data on TSD carrier screening in these groups. No new benchmark datasets were introduced; rather, the study evaluated existing screening methodologies on a novel population.

Key Insights and Ideas

  • Enzyme Assay Limitations in Non-AJ Populations: The study strongly suggests that the standard enzymatic assay for Hex A activity, with reference ranges likely derived from AJ populations, produces a disproportionately high number of "inconclusive" and "positive" results in African/African American and Hispanic individuals. This indicates that the established thresholds may not be universally applicable.
  • Ethnic Differences in Hex A Activity: Emerging data suggest that African American populations may have, on average, slightly lower Hex A activity levels. This biological difference could contribute to the higher rates of non-negative enzymatic results, leading to potential over-diagnosis of carriers.
  • NGS as a More Reliable Alternative: Next-generation sequencing of the HEXA gene demonstrated a much better correlation with the expected carrier frequency in the general population. While enzymatic assays flagged many individuals, sequencing identified only one individual with a likely deleterious mutation among those tested.
  • The Challenge of "Inconclusive" Results: The high rate of inconclusive enzymatic results poses a significant challenge for clinical management, often necessitating further testing and potentially causing patient anxiety without a clear diagnosis.
  • Limitations of Targeted Mutation Analysis: Targeted mutation analysis, which focuses on a limited set of known mutations, is less effective for carrier detection in diverse populations where different mutations may be present.

Key Results

  • Out of 508 patients tested, 4.9% (25 individuals) had positive enzymatic results, and 7.9% (40 individuals) had inconclusive results.
  • Of the 12 patients who underwent full HEXA gene sequencing after positive or inconclusive enzyme results, only one patient carried a likely deleterious mutation (c.1510C>T).
  • The remaining 11 sequenced patients did not carry a pathogenic variant; nine had multiple known benign variants, and two had no detectable variants.
  • The positive enzyme result rate in this cohort (4.9%) was significantly higher than the expected carrier frequency in the general low-risk population (~1/300).
  • The positive rate by NGS in this study was consistent with general population expectations, suggesting the enzyme assay's results were not accurately reflecting carrier status in this demographic.

Limitations and Future Work

  • Sample Size for Sequencing: While 508 patients underwent initial screening, only 12 proceeded to full HEXA gene sequencing. This relatively small number for sequencing limits the generalizability of the molecular findings.
  • NGS Limitations: The NGS assay used in this study could not detect certain types of pathogenic variants, such as copy number variations (other than the specific 7.6kb deletion), inversions, or intronic variants.
  • Ethnic-Specific Reference Ranges: The authors strongly suggest the need for ethnic-specific recalibration of Hex A enzyme reference ranges for non-AJ populations.
  • NGS as Primary Screening: The paper advocates for considering NGS as the primary screening modality for TSD in non-AJ populations, given its higher accuracy and comparability to or better performance than enzymatic analysis.
  • Continued Data Collection: The authors plan to continue collecting data on non-negative enzyme results to identify any unrealized pathogenic variants or pseudodeficiency alleles and to improve the clinical sensitivity of NGS assays.

Summary updated

Abstract

High inconclusive rates and poor correlation between positive/inconclusive enzyme results and identification of pathogenic mutations suggest that ethnic-specific recalibration of reference ranges for EA may be necessary. Alternatively, HEXA gene sequencing could be performed.
BibTeX
@inproceedings{mehta2016tay,
  author = {Nikita Mehta and Gabriel A. Lazarin and Erica Spiegel and Kathleen Berentsen and Kelly Brennan and Jessica L. Giordano and Imran S. Haque and Ronald J. Wapner},
  title = {{Tay-Sachs Carrier Screening by Enzyme and Molecular Analyses in the New York City Minority Population}},
  booktitle = {Genetic},
  year = {2016},
  doi = {10.1089/gtmb.2015.0302},
}
Figure